Conditions: Chronic Plaque Psoriasis
Keywords: Efalizumab Chronic Plaque Psoriasis Transition from systemic therapies on to Efalizumab
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 70
Healthy volunteers: no

Brief summary:
To assess the safety of transitioning subjects to Raptiva therapy from standard oral systemic or phototherapy by overlapping with Raptiva whilst tapering the initial systemic therapy or phototherapy dose.

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)
Intervention descriptions: intervention 1: Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.

Protocol document: